Piramal Pharma
PPLPHARMA · NSEValuation
Blended fair value using DCF and peer comparison methods.
Peer comparison
How this company stacks up against sector peers on valuation and quality metrics.
Branded generics & specialty pharma · 8 peers · sector medians shown
| Company | Mkt Cap | P/E | P/B | EV/EBITDA | ROE | Net Margin | Rev CAGR 3y |
|---|---|---|---|---|---|---|---|
Piramal Pharma PPLPHARMA · you | ₹19,297 Cr | 33.7× | 2.7× | 32.3× | -4.0% | -3.7% | 7.8% |
| Sector median | — | 36.1× | 4.9× | 24.6× | 12.9% | 14.5% | 12.7% |
| Mankind Pharma MANKIND | ₹98,725 Cr | 51.7× | 6.0× | 29.1× | 11.7% | 13.4% | 17.7% |
| Aurobindo Pharma AUROPHARMA | ₹83,993 Cr | 24.1× | 2.2× | 12.5× | 9.2% | 10.4% | 10.6% |
| Biocon BIOCON | ₹67,470 Cr | 145.1× | 1.9× | 25.6× | 1.1% | 2.3% | 14.8% |
| Alkem Laboratories ALKEM | ₹63,998 Cr | 27.8× | 4.6× | 22.8× | 16.7% | 15.6% | 8.2% |
| Abbott India ABBOTINDIA | ₹55,558 Cr | 35.7× | 11.6× | 29.4× | 32.5% | 22.4% | 9.0% |
| Ipca Laboratories IPCALAB | ₹41,806 Cr | 36.3× | 5.1× | 22.4× | 14.2% | 11.8% | 15.6% |
| Gland Pharma GLAND | ₹37,695 Cr | 36.8× | 3.6× | 23.5× | 9.9% | 16.0% | 21.1% |
| Glaxosmithkline Pharmaceuticals GLAXO | ₹37,177 Cr | 35.9× | 16.4× | 28.3× | 45.7% | 27.1% | 5.5% |
Piramal is fairly valued relative to sector peers — trading near the sector median on key multiples (P/E ~36.1×, EV/EBITDA ~24.6×). Focus on execution quality and earnings trajectory from here.
Business quality
Key profitability, efficiency, and solvency metrics.
Financial health
Piotroski F-Score, Altman Z-Score, and key solvency ratios.
Full financial data
Charts and annual statements for income, balance sheet and cash flow.
Income trend
Revenue, profit and margin trends over time.
Cash flow
Where cash comes from and where it goes.
Balance sheet
Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.
How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.